Genomics Reporting Implementation Guide
4.0.0-cibuild - CI Build

Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 4.0.0-cibuild built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

## Example DiagnosticReport: somaticReport

Page standards status: Informative

Profile: Genomic Report

## Genetic analysis report (Genetics)

When For | 2023-02-02
Performers | Practitioner Test Dolin Organization My Test Pathology Laboratories
Identifier | Accession ID/23-0000345

Report Details

Code | Value | Flags | Note | When For | Reported
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Genetic variant assessment | Present | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Diagnostic Implication |  | Final |  | 2023-02-01 |
Therapeutic Implication |  | Final |  | 2023-02-01 |
Therapeutic Implication |  | Final |  | 2023-02-01 |
Therapeutic Implication |  | Final |  | 2023-02-01 |
Therapeutic Implication |  | Final |  | 2023-02-01 |
Therapeutic Implication |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Molecular Consequence |  | Final |  | 2023-02-01 |
Mutations/Megabase [# Ratio] in Tumor | 29.8 | Final |  | 2023-02-01 |
Microsatellite instability [Interpretation] in Cancer specimen Qualitative | MSI-H | Final |  | 2023-02-01 |
PD-L1 by clone 22C3 in Tissue by Immune stain Report | Positive | Final | 5% tumor proportion score | 2023-02-01 |
Haplotype Name | HLA-A*24:02 | Final |  | 2023-02-01 | 2023-02-01 00:00:00-0500
Haplotype Name | HLA-A*02:06 | Final |  | 2023-02-01 | 2023-02-01 00:00:00-0500
Haplotype Name | HLA-B*35:01 | Final |  | 2023-02-01 | 2023-02-01 00:00:00-0500
Haplotype Name | HLA-B*35:01 | Final |  | 2023-02-01 | 2023-02-01 00:00:00-0500
Haplotype Name | HLA-C*03:03 | Final |  | 2023-02-01 | 2023-02-01 00:00:00-0500
Haplotype Name | HLA-C*15:02 | Final |  | 2023-02-01 | 2023-02-01 00:00:00-0500

Patient is positive for Tier 1 / Level A variants, including variants with FDA-approved indications.

Coded Conclusions:

- Positive